Evidence map›Paper›PMID 40099066›Full record

ArticleCureus2025

Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma.

Kou Kimoto, Hitoshi Kawasuji, Yoshihiro Yoshida, Hiroshi Yamada, Shunsuke Yazawa, Hideki Tani, Yuki Koshiyama, Yoshimi Nabe, Shohei Kikuchi, Kentaro Nagaoka and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kou KimotoDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.
Hitoshi KawasujiDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.
Yoshihiro YoshidaDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.
Hiroshi YamadaDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.
Shunsuke YazawaDepartment of Virology, Toyama Institute of Health, Imizu, JPN.
Hideki TaniDepartment of Virology, Toyama Institute of Health, Imizu, JPN.
Yuki KoshiyamaDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.
Yoshimi NabeDepartment of Hematology, University of Toyama, Toyama, JPN.
Shohei KikuchiDepartment of Hematology, University of Toyama, Toyama, JPN.
Kentaro NagaokaDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.
Yoshitomo MorinagaDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.
Yoshihiro YamamotoDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 58-year-old male developed three coronavirus disease 2019 (COVID-19) relapses within three months after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy against relapsed follicular lymphoma. Five- and 10-day remdesivir courses failed to achieve viral clearance. A 30-day nirmatrelvir/ritonavir course provided symptom resolution and sustained reverse transcription and quantitative polymerase chain reaction (RT-qPCR) negativity. Genome analyses identified cultured live virus (day 59) and nasopharyngeal-swab viral RNA (days 74, 82, 95) as Omicron BA.5 sublineage BF.13. Normal immunoglobulin (Ig)G levels and high neutralizing activities against BA.5 were maintained throughout the infection's course. Extended nirmatrelvir/ritonavir antiviral treatment may be effective for patients administered anti-CD20 therapy who develop prolonged/relapsed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection despite possessing high neutralizing activities.

Indexed as

bf.13covid-19multi-relapsenirmatrelvir/ritonavirr-chop

Identifiers

PMID40099066
PMCPMC11911031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.